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Background: In many tumour types serumlactate dehydrogenase (LDH) levels proved to represent an indirect
marker of tumour hypoxia, neo-angiogenesis and worse prognosis. As we previously reported LDH is an important
predictive factor in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).
Sorafenib represents the therapeutic stronghold in advanced HCC patients. As a tyrosine kinase inhibitor (TKI) mainly
directed against the angiogenetic pathway, the correlation of sorafenib administration with markers of hypoxia
could be an important tool in patients management. Aim of our analysis was to evaluate the role of LDH
pre-treatment levels and its variation during treatment in HCC patients receiving sorafenib.
Methods: 78 patients were available for our analysis. For all patients LDH values were collected within one month
before the start of treatment and after the end of therapy. For study purposes we divided our patients into two
groups, according to LDH pre-treatment levels, cut-off levels was determined with ROC curve analysis. Patients were,
also, classified according to the variation in LDH serum levels pre- and post-treatment (increased vs decreased).
Results: Patients proved homogeneous for all clinical characteristics analyzed. In patients with LDH values under
the cut-off median progression free survival (PFS) was 6.7 months, whereas it was 1.9 months in patients above the
cut-off (p = 0.0002). Accordingly median overall survival (OS) was 13.2 months and 4.9 months (p = 0.0006). In
patients with decreased LDH values after treatment median PFS was 6.8 months, and median OS was 21.0 months,
whereas PFS was 2.9 months and OS 8.6 months in patients with increased LDH levels (PFS: p = 0.0087; OS: p = 0.0035).
Conclusions: In our experience, LDH seemed able to predict clinical outcome in terms of PFS and OS for HCC patients
treated with sorafenib. Given the correlation between LDH levels and tumour angiogenesis we can speculate that
patients with high LDH pretreatment levels may be optimal candidates for other emerging therapeutic agents or
strategies targeting different molecular pathways.
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Hepatocellular carcinoma (HCC) represents the common-
est primary cancer of the liver. Incidence is increasing and
HCC has risen to become the 5th commonest malignancy
worldwide and the third leading cause of cancer related
death, exceeded only by cancers of the lung and stomach
[1]. Surgery is the only potentially curative treatment
for HCC. In carefully selected patients, resection and
transplantation in fact, allow a 5 years survival ranging
from 60 to 70%, and should be considered as a first
treatment option in this setting [1].
Unfortunately most patients in Western countries
present with an advanced HCC at diagnosis with the
consequent impossibility to use curative treatments.
In these patients prognosis is poor with a median survival
of less than 1 year [1].
In the last few years the introduction of sorafenib, an
oral multi-tyrosine kinase inhibitor (TKI) for the treat-
ment of advanced HCC patients changed the clinical
landscape for these tumours and now represents the
standard of care [2-4].
However a large proportion of patients still does not
seem to benefit from such a treatment approach and are
therefore exposed to unnecessary toxicity [2-4].
Clinical or molecular criteria allowing a more accur-
ate selection of resistant/responder tumours are in fact
largely lacking, although they would be obviously cru-
cial for an optimal management of these patients in the
clinical practice [5].
Hypoxia represents a clinical biological mechanism for
treatment resistance in cancer cells via the formation of
new blood vessels. Furthermore, a growing body of evi-
dence indicates that hypoxia might actually promote can-
cer development. Lactic dehydrogenase (LDH), which is a
glycolytic enzyme, composed of four polypeptide chains,
each one encoded by separate gene (M and H), exists in
various types of human tissue and neoplasms. LDH is a
key enzyme in the conversion of pyruvate to lactate under
anaerobic conditions [6]. Five isoforms of LDH have been
identified as a result of the five different combinations
of polypeptide subunits [7]. In preclinical models up-
regulation of LDH has been suggested to ensure both
an efficient anaerobic/glycolytic metabolism and a reduced
dependence on oxygen under hypoxic conditions in tumor
cells. The biological link between hypoxia, LDH levels
and the tumor-driven angiogenesis pathway through
the abnormal activation of the hypoxia inducible factor
1 (HIF-1) is well established. The biological activity of
HIF-1 is determined by the expression and activity of
the HIF-1α subunit [8]. HIF-1α is an essential factor
that up regulates a series of genes involved in glycolytic
energy metabolism, angiogenesis, erythropoiesis and
cell survival [9]. Hypoxia in the tumor microenvironment is
sufficient to activate HIF-dependent expression of severaldownregulated genes [10]. These include genes encoding
for vascular endothelial growth factor, erythropoietin and
many enzymes involved in glucose, iron, and nucleotide
metabolism [11].
Although links among these factors are well known,
their translation into clinical practice is still poorly investi-
gated. The aim of our analysis is to assess the role of LDH
serum concentration in a population of advanced HCC
patients, treated with sorafenib.
Methods
Patients selection
This is a retrospective multicentre analysis. Two centres in
Italy (Translational Oncology Unit and Gastroenterology
Department, AOU “Ospedali Riuniti” – Università
Politecnica delle Marche, Ancona; Internal Medicine,
Department of Medical Sciences Experimental and Clinical -
Università di Udine, Udine) were involved in the study.
From 2008 to 2012, consecutive patients with advanced
HCC or intermediate stage HCC refractory to or un-
suitable for locoregional therapies, either histologically
proven or diagnosed according to the AASLD guidelines
(American Association for the Study of Liver Diseases 2005)
and receiving sorafenib were eligible for our analysis.
All patients received sorafenib with standard schedule
(400 mg bid continuously) dose reduction was applied
as clinically indicated. Follow-up consisted of physical
examination, a complete blood count, alpha-fetoprotein
(α-FP) assay, computed tomography or magnetic resonance
imaging (CT/MRI) scanning as clinically indicated. Tumour
response was evaluated every 8 weeks by clinicians’ assess-
ment imaging and according to the modified Response
Evaluation Criteria in Solid Tumours (mRECIST) [12].
Radiological images were reviewed in double-blind by
two radiologists.
Patients were classified according to ECOG PS (Eastern
Cooperative Oncology Group performance status) and
were staged using Child-Pugh and BCLC (Barcelona Clinic
Liver Cancer) classifications.
In order to investigate whether LDH might be used as an
early predictor of sorafenib failure we recorded LDH serum
levels pre- (within 1 month prior the start of sorafenib
treatment) and post-treatment (within one month after
the end of sorafenib treatment). LDH serum levels were
determined according to IFCC (International Federation
of Clinical Chemistry and Laboratory Medicine) method.
The assay has been conducted in Institution Laboratories
certified for Quality control according to the present rules
in Europe (ISO 9001:2008). The study received clearance
by the local Ethical Committee.
Statistical analysis
Statistical analysis was performed with MedCalc software
version 10.4.8 for Windows. Patients were divided into two
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value determined with receiver operating characteristics
(ROC) curve analysis. Patients were, also, classified ac-
cording to any variation in LDH serum levels pre- and
post-treatment (increased vs. decreased).
The association between categorical variables was es-
timated by χ2 test. Survival distribution was estimated
by the Kaplan–Meier method.Table 1 Clinical variables examined
Clinical variables LD
≤407
Patients 53 (
Gender Male 52 (
Female 1 (
Median age < 69 28 (
≥ 69 25 (
ECOG 0 36 (
1-2 17 (
BCLC B 14 (
C 39 (
Median serum α-FP level ≥ 19 ng/mL 13 (
< 19 ng/mL 40 (
Comorbidities (>5%) Cardiovascular 11 (
Diabetes 6 (1
Other previous neoplasm 3 (
Etiology HCV 20 (
HBV 13 (
HBV-HCV 2 (
Alcoholic 9 (1
Alcoholic - HBV-HCV 0 (
Methabolic-Cryptogenetic 9 (1
Prior locoregional treatments Yes 25 (
No 28 (
Prior surgery Yes 11 (
No 42 (
AST < UNR (40 U/L) 19 (
≥ UNR (40 U/L) 34 (
ALT < UNR (40 U/L) 23 (
≥ UNR (40 U/L) 30 (
CRP < UNR (0.5 mg/dL) 11 (
≥ UNR (0.5 mg/dL) 42 (
Viral load HCV RNA < 5.3 log10 IU/mL 7 (3
≥ 5.3 log10 IU/mL 13 (
Viral load HBC DNA < 2000 IU/mL 6 (4
≥ 2000 IU/ml 7 (5
ECOG PS (Eastern Cooperative Oncology Group performance status), BCLC (Barcelona C
CRP (C reactive protein), UNR (upper normal rate).Significant differences in probability of survival between
the strata were evaluated by log-rank test.
A significant level of 0.05 was chosen to assess the
statistical significance.
Cox’s multiple regression analysis was used to assess
the role of polymorphisms as prognostic factors ad-
justed for those variables resulted significant at univar-
iate analysis.H LDH LDH LDH Total
U/l >407 U/l Decreased Increased
%) 25 (%) 26 52 78
98) 21 (84) 24 (92) 49 (94) 73
2) 4 (16) 2 (8) 3 (6) 5
53) 11 (44) 12 (46) 27 (52) 39
47) 14 (56) 14 (54) 25 (48) 39
68) 16 (64) 15 (58) 37 (71) 52
32) 9 (36) 11 (42) 15 (29) 26
26) 10 (40) 8 (32) 16 (31) 24
74) 15 (60) 18 (68) 36 (69) 54
25) 7 (28) 5 (19) 15 (29) 20
75) 18 (72) 21 (81) 37 (71) 58
21) 4 (16) 5 (19) 10 (19) 15
1) 2 (8) 3 (12) 5 (10) 8
6) 0 (0) 1 (4) 2 (4) 3
38) 9 (36) 10 (38) 19 (37) 29
24) 7 (28) 5 (19) 15 (29) 20
4) 0 (0) 1 (4) 1 (2) 2
7) 5 (20) 7 (27) 7 (13) 14
0) 1 (4) 0 (0) 1 (2) 1
7) 3 (12) 3 (12) 9 (17) 12
47) 13 (52) 15 (58) 23 (44) 38
53) 12 (48) 11 (42) 29 (56) 40
21) 4 (16) 6 (23) 9 (17) 15
79) 21 (84) 20 (77) 43 (83) 63
36) 9 (36) 14 (54) 14 (27) 28
64) 16 (64) 12 (46) 38 (73) 50
43) 11 (44) 9 (35) 25 (48) 34
57) 14 (56) 17 (65) 27 (52) 44
21) 4 (16) 6 (23) 9 (17) 15
79) 21 (84) 20 (77) 43 (83) 63
5) 5 (56) 3 (30) 9 (47) 12
65) 4 (44) 7 (70) 10 (53) 17
6) 3 (43) 3 (60) 6 (40) 9
4) 4 (57) 2 (40) 9 (60) 11
linic Liver Cancer), AST (aspartate aminotransferase), ALT (alanine aminotransferase),
Figure 2 ROC curve for OS.
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free survival (PFS) were defined as the interval between
the date of beginning of sorafenib treatment to death or
last follow-up visit, and to clinical progression or death
or last follow-up visit if not progressed.
The clinical variables analyzed were: gender (male vs.
female), age (≤69 years vs. >69 years), ECOG PS (0 vs. 1–2),
Child-Pugh score (A vs. B), BCLC stage (A vs. B-C),
median serum α-FP level (≥19 vs. <19), comorbidities
(>5%) (cardiovascular, diabetes, other previous neoplasm),
etiology (HCV, HBV, Alcoholic, Methabolic-Cryptogenetic),
aspartate aminotransferase (AST) serum levels (<UNR
vs. ≥UNR upper normal rate 40U/L), alanine amino-
transferase (ALT) serum levels (<UNR vs. ≥UNR upper
normal rate 40U/L), C reactive protein (CRP) serum
levels (<UNR vs. ≥UNR upper normal rate 40U/L), HCV
(<5.3 log10 IU/mL vs. ≥5.3 log10 IU/mL) and HBV
(<5.3 log10 IU/mL vs. ≥5.3 log10 IU/mL) viral loads.
Results
Seventy-eight patients were available for our analysis: 72
(92%) males and 6 (8%) females. Median age was 69 years
(range 51–84) (Table 1). All patients were in Child-Pugh
class A. Sorafenib dose reduction was applied in 16 patients
(21%) with grade 3 and 4 toxicities. In the general popula-
tion median PFS was 4.0 months, while median OS was
10.7 months.
The cut-off point with the highest sensitivity and spe-
cificity for estimating pre-treatment LDH serum levels
as a function of treatment clinical activity was set after
ROC curve analysis at ≤ 407 U/l both for PFS (Figure 1)
and OS (Figure 2).Figure 1 ROC curve for PFS.Fifty-three patients (68%) showed pretreatment LDH
serum levels below the cut-off, while 25 (32%) were found
above the chosen cut-off. Twenty-six patients (33%) showed
decreased LDH serum levels after treatment, while in
52 (67%) this value increased.
At univariate analysis patients with LDH values below
the cut-off median PFS was 6.7 months, whereas it was
of 1.9 months in patients above the cut-off (p = 0.0002;
HR: 2.79; IC: 1.27-6.15) (Figure 3). Accordingly median
OS was 13.2 months and 4.9 months in the two groups
(p = 0.0006 HR: 2.74; IC: 1.22-6.16) (Figure 4). In patients
with decreased LDH values after treatment median
PFS was 6.8 months, and median OS was 21.0 months,
whereas PFS was 2.9 months and OS was 8.6 in patients
with increased LDH levels (PFS: p = 0.0087; HR: 0.48; IC:
0.27-0.84; Figure 5; OS: p = 0.0035; HR: 0.42; IC: 0.23-0.65;
Figure 6).
A statistical significant difference in term of PFS and OS
was found between patients in B (24 pts) or C (54 pts)
stage of BCLC classification (PFS: 7.6 stage B vs. 3.3 stage C,
p = 0.0364; OS: 18.4 stage B vs. 9.6 stage C, p = 0.0233).
At multivariate analysis LDH serum levels pre-treatment,
the variation post-treatment and BCLC stage emerged
as independent prognostic factors predicting outcome
in terms of PFS (respectively: p = 0.0197, HR = 0.71;
p = 0.0201, HR = 0.19; p = 0.0016, HR = 0.35) and OS
(respectively: p = 0.0011, HR = 0.69; p = 0.0039, HR = 0.24;
p = 0.0051, HR = 0.39).
No statistically significant differences were found accord-
ing to other clinical characteristics analyzed (Table 1).
Toxicity profiles between patients groups are reported
in Table 2.
Figure 3 PFS according to LDH pre-treatment: LDH ≤ 407 U/l (———), LDH >407 U/l (——————) (p = 0.0002).
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The introduction of antiangiogenic drugs in HCC
treatment saw a wide shift in patients outcome, al-
though a good initial response is observed, frequently
this results in a subsequent loss of efficacy. Besides in
clinical trials a considerable proportion of patients
ranging from 20% to 38% discontinued sorafenib due
to adverse events [13-15].
A better selection of patients more likely to benefit
from sorafenib treatment, avoiding unnecessary toxicities to
those potentially resistant, may be then clinically relevant.Figure 4 OS according to LDH pre-treatment: LDH ≤ 406 U/l (———),In our experience, LDH serum levels seemed able to
predict clinical outcome in terms of PFS and OS for HCC
patients treated with sorafenib. We recently reported LDH
has a predictive role in terms of PFS and OS in HCC pa-
tients treated with transarterial chemoembolization (TACE)
[16]. Also Kohles et al. showed a possible prognostic role of
pretreatment LDH serum levels in HCC patients undergo-
ing TACE [17], confirming our hypothesis.
These findings are also in accordance with previously
published analyses suggesting a relationship between LDH
levels and a worse outcome in other tumor types [18].LDH >406U/l (——————) (p = 0.0006).
Figure 5 PFS according to LDH variations pre- and post-treatment: increased (———), decreased (——————) (p = 0.0087).
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correlated with high LDH serum levels and also an high
LDH associates with a decreased median overall survival
in colorectal cancer patients [19,20].
A strong association has also been demonstrated between
the expression of LDH, in particular the LDH-5 isoform
and an aggressive phenotype in gastric cancer [21].
Hypoxia and angiogenesis are probably the mechanisms
involved in high LDH serum levels and are correlated with
enhanced tumour aggressiveness and thus worse prognosis.
Two different clinical trials (CONFIRM 1&2) asserting
the efficacy of PTK/ZK (vatalanib), an oral inhibitor ofFigure 6 OS according to LDH variations pre- and post-treatment: incvascular endothelial growth factor (VEGF, in colorectal
cancer patients, investigated also the correlation between
tumour angiogenesis and LDH levels. Subsequent analyses
from these trials in fact evidenced an improved median PFS
with the use of PTK/ZK in patients with high serum LDH
levels, thus suggesting that tumor angiogenesis represent a
key crucial event in presence of high LDH levels [22,23].
In addition to a better prognosis for patients with ab-
solute low LDH level, we demonstrated that a decrease
of LDH level during treatment seems to predict a better
outcome of HCC patients treated with sorafenb. These
findings seem to suggest that the biological phenomenonreased (———), decreased (——————) (p = 0.0035).
Table 2 Toxicity profile between patients groups
Clinical variables LDH LDH LDH LDH Total
≤407
U/l
>407
U/l
Decreased Increased
Patients 53 (%) 25 (%) 26 52 78
Any grade
toxicity
Global 24 (45) 9 (36) 13 (50) 20 (38) 33
Rash 5 (9) 3 (12) 4 (15) 4 (8) 8
Hand-foot 9 (17) 4 (16) 7 (27) 6 (12) 13
Nausea/
vomiting
3 (6) 2 (8) 1 (4) 4 (8) 5
Diarrhea 11 (21) 3 (12) 6 (23) 8 (15) 14
Fatigue 5 (9) 5 (20) 4 (15) 6 (12) 10
Liver
dysfunction
0 (0) 2 (8) 1 (4) 1 (2) 2
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influenced by medical treatment.
In accordance to this suggestion a single experience of
Fiume et al. showed how inhibiting LDH production
with oxamic acid in cancer cell lines potentiated the
antiproliferative activity of tyrosine kinase inhibitors,
such as sorafenib [24].
Conclusions
We can then speculate that patients with high LDH
pretreatment levels may be optimal candidates for clinical
trial exploring a multimodality treatment approach.
After confirmation in larger analyses we believe that
LDH should be considered as a relevant biological variable
to be included in the baseline set up of HCC patients,
with the aim to better define the most appropriate thera-
peutic strategy and to better stratify patients included in
clinical trials.
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